Ex vivo corneal epithelial wound healing following exposure to ophthalmic nonsteroidal anti-inflammatory drugs | Zendy

McDermott | Zendy; Keping Xu | Zendy; Linda Villanueva | Zendy; Rhett M. Schiffman | Zendy; David Hollander | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Ex vivo corneal epithelial wound healing following exposure to ophthalmic nonsteroidal anti-inflammatory drugs

Author(s) -

McDermott,

Keping Xu,

Linda Villanueva,

Rhett M. Schiffman,

David Hollander

Publication year - 2011

Publication title -

clinical ophthalmology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.025

H-Index - 56

eISSN - 1177-5483

pISSN - 1177-5467

DOI - 10.2147/opth.s16778

Subject(s) - ketorolac , medicine , ketorolac tromethamine , wound healing , nonsteroidal , tolerability , ophthalmology , anesthesia , pharmacology , surgery , adverse effect , analgesic

Ketorolac 0.45% is a new formulation of topical ketorolac in which preservative (benzalkonium chloride, BAK) was removed and carboxymethylcellulose (CMC) was added to improve tolerability and reduce dosing frequency. This study compared the effects of ketorolac 0.45% on corneal wound healing to prior ketorolac formulations (0.4% and 0.5%), bromfenac 0.09%, and nepafenac 0.1%.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research